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Background: Microporous Polysaccharide Hemospheres (MPH) are a new plant-derived
polysaccharide powder hemostat. Previous studies investigated MPH as a replacement to
nonflowable hemostatic agents of different application techniques (e.g., oxidized cellulose,
collagen); therefore, the purpose of this study was to determine if MPH is a surrogate for
flowable hemostatic agents of similar handling and application techniques, specifically a
flowable thrombin-gelatin hemostatic matrix.
Methods: Hemostatic efficacy was compared using a heparinized porcine abrasion model
mimicking a capsular tear of a parenchymal organ. MPH (ARISTA, 1 g) and hemostatic
matrix (Floseal, 1 mL) were applied, according to a randomized scheme, to paired hepatic
abrasions (40 lesions per group). Hemostatic success, control of bleeding, and blood loss
were assessed 2, 5, and 10 min after treatment. Hemostatic success and control of bleeding
were analyzed using odds ratios and blood loss using mean differences.
Results: Hemostatic matrix provided superior hemostatic success relative to MPH at 5 (odds
ratio: 0.035, 95% confidence interval: 0.004e0.278) and 10 min (0.032, 0.007e0.150), provided
superior control of bleeding at 5 (0.006, <0.001e0.037) and 10 min (0.009, 0.001e0.051), and
had significantly less blood loss at 5 (mean difference: 0.3118 mL/min, 95% confidence
interval: 0.0939e0.5296) and 10 min (0.5025, 0.2489e0.7561).
Conclusions: These findings corroborate other MPH investigations regarding its low-level
efficacy and suggest that MPH is not an appropriate surrogate for hemostatic matrix
despite similar application techniques. The lack of a procoagulant within MPH may likely
be the reason for its lower efficacy and need for multiple applications.
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class of absorbable hemostatic agents is polysaccharide
spheres produced from plant-derived starch. This new class
includes microporous polysaccharide hemospheres (MPH).
Murat et al. [2] first described the hemostatic agent as a
plant-derived starch. MPH has a porous surface, which ab-
sorbs water and low molecular weight compounds,
<40,000 Da, from the blood to concentrate blood solids [2]. The
use of MPH is documented in a series of animal models [2e9].
These studies use noncoagulopathic animal models and
compare MPH with other low-end hemostatic agents, for
example, oxidized cellulose and collagen pad. MPH has not
been compared in a clinically relevant animal model with a
flowable hemostatic matrix agent of similar handling char-
acteristics and application techniques.
Prior et al. [10] first described flowable hemostatic matrix as
a combination of fibrillar collagen, bovine thrombin, and
autologous plasma. Recent investigations, however, demon-
strated that the most effective flowable hemostatic matrix is a
combination of human thrombin and bovine gelatin [11]. The
effectiveness of this hemostatic matrix is believed to be due to
the unique gelatin shape and properties. This flowable hemo-
static matrix has been demonstrated to be effective in several
human studies across multiple surgical specialties [12e14].
Given the lack of comparative studies betweenMPH and agents
of similar handling characteristics and application technique,
this study compares the hemostatic efficacy of MPH and a
flowable hemostatic matrix in a heparinized porcine abrasion
model. This surgical model mimics a capsular tear of a paren-
chymal organ experienced during surgery. The null hypothesis
is that the agents will have equal hemostatic efficacy.2. Methods and materials
2.1. Hemostatic agents
Microporous polysaccharide hemospheres (MPH) are ARISTA
AH (Medafor, Inc, Minneapolis, MN). MPH is produced by the
reaction of epichlorohydrin with a highly purified potato
starch solution that is then irradiated for sterility. In a pro-
spective, multicenter, randomized, controlled clinical study,
MPH was noninferior to a collagen hemostatic pad. Flowable
hemostatic matrix is Floseal VH S/D (Baxter Healthcare Cor-
poration, Deerfield, IL). The hemostatic matrix is composed of
human-derived thrombin and bovine-derived gelatin. In three
prospective, multicenter, randomized, controlled clinical
studies, hemostatic matrix was superior to a collagen hemo-
static pad prepared with thrombin [12e14].
2.2. Heparinized porcine hepatic abrasion model
A heparinized porcine hepatic abrasion model was used to
mimic intraoperative capsular tears. Themodel is a literature-
accepted animal model to compare hemostatic agents
[11,15,16] and is representative of an appropriate application
of each hemostatic agent based on previous published uses
[3,11]. All animal activities were performed according to the
Guide for the Care and Use of Laboratory Animals and the
United States Animal Welfare Act in an institution accreditedby the Association for Assessment and Accreditation of Lab-
oratory Animal Care International (AAALAC) following Insti-
tutional Animal Care and Use Committee approval.
A total of six female Yorkshire pigs were used for this study
for ease of handling and husbandry. Each animal was preop-
eratively medicated with ketamine (20 mg/kg, intramuscu-
larly [IM]), xylazine (2 mg/kg, IM), and atropine (0.05 mg/kg,
IM), after which each was mask induced using isoflurane (up
to 5% of inhaled air) in a 2:1 nitrous oxide to oxygen carrier.
Peri- and intra-operatively, all pigs received a continuous rate
infusion of crystalloid solution. Each animal was heparinized
to at least two times greater than their baseline activated
clotting time to mimic the clinical situation throughout the
study. This level of heparinization gives a clinically relevant
activated clotting time of 200 s [8].
Once at a surgical plane, a celiotomy was performed to
expose the liver lobes without compressing the hepatic
vasculature. The consistent hepatic vascular architecture that
lacks a vasoconstriction response provides consistent and
reproducible bleeds [17]. A series of two hepatic abrasions, 1 cm
diameter and 0.3e0.4-cm deep, were created using a hand drill
fixed with sandpaper. Bleeding of each lesion was scored as 0,
1, 2, 3, 4, or 5, which represented “no bleeding,” “ooze,” “very
mild,” “mild,” “moderate,” and “severe,” respectively. A lower
bleeding score was equated to a greater control of bleeding.
The series of abrasions were treated with either MPH or the
hemostatic matrix according to a randomized scheme not seen
by the surgical investigator until the time of treatment. Each
hemostatic agentwaspreparedaccording to themanufacturer’s
instructionsforuse.A total of 1gofMPHanda total of 1mLof the
hemostatic matrix were applied once to each assigned lesion.
After application, each agent was approximated to the bleeding
site using gauze and digital pressure for 2 min. The gauze was
then removed, and the treated lesionswere assessed at 2, 5, and
10 min after treatment according to the previously mentioned
standardized score by the same surgical investigator who
created the lesions. Treated lesions were simultaneously and
equally irrigated after the 5 min assessment to remove excess
material. Only one surgical investigator created, treated, and
assessedthe lesions throughoutthestudytoensureconsistency.
A bleeding score of 0 and 1 were considered as hemostatic
success. Blood loss from each lesion was measured using
preweighed gauze held to each lesion for 1 min then
reweighed. Grams of blood loss were then converted to mil-
liliters per minute, where 1 g equaled 1 mL.
2.3. Statistical analysis
The study was designed with the goal that 80 lesions (40 per
group) would be evaluated and sufficient to detect a difference
in rates of 75% versus 35% (i.e., 40%) with an alpha of 0.05 and a
power of 90%. A 40% difference in efficacy is deemed clinically
meaningful based on previous studies [11,15,16]. The statistical
analysis was performed using SAS (SAS Institute Inc, Cary, NC).
For bleeding score, logistic regression was used to evaluate
the treatment effect at 2, 5, and 10 min after treatment using
SAS procedure LOGISTIC in the following two ways: assuming
a binomial model on percent hemostatic success with a score
1 and assuming a proportional odds model on observed
control of bleeding. In doing so, the odds ratio for “MPH” and/
Fig. 1 e Floseal (hemostatic matrix) provides and
maintains greater hemostasis than ARISTA AH (absorbable
hemostatic particles) in a heparinized porcine hepatic
abrasion model of a capsular tear. Statistical significance is
based on a binomial odds ratio (* 0.035, 95% CI:
0.004e0.278; ** 0.032, 0.007e0.150; n [ 40 per group per
time point).
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were computed at each time point after treatment.
For blood loss, a general linear model was used to evaluate
the treatment effect at 2, 5, and 10 min after treatment using
SAS procedure MIXED. In doing so, the mean difference for
“MPH”-“hemostatic matrix” and its 95% CIs were computed at
each time point after treatment. Independent variables for all
models included treatment group, pig, liver lobe (medial,
right, or left), and initial bleeding score (at 0 min, untreated).3. Results
Six pigs were used to create and treat a total of 40 lesions per
group. The volume of product applied proved sufficient for the
size of lesion created for both treatments. The hemostatic
success of hemostatic matrix was 17.5%, 40%, and 57.5%
greater than MPH at 2, 5, and 10 min after application,
respectively (Fig. 1).Table 1 e Floseal (hemostatic matrix) provides superior hemos
AH (absorbable hemostatic particles).
Statistical analysis Time point after
treatment (min)
Pig effect
P value
Lobe effect
P value
Hemostatic success 5 0.1672 0.2827
10 0.3064 0.7042
Control of bleeding 5 0.0403 0.1280
10 0.0033 0.4309
Significance is based on a binomial model on percent hemostatic succe
Covariate effects that were not significant were removed to compute the o
as probability of success divided by oneminus this probability. The odds r
the odds ratio is equal to one, then the two treatment groups are equal.Based on the odds ratio for hemostatic success, hemostatic
matrix was statistically superior to MPH at 5 (odds ratio: 0.035,
95% CI: 0.004e0.278) and 10 min (0.032, 0.007e0.150) after
application (Table 1). No covariate effectswere significant, and
all were removed to compute the odds ratios and their confi-
dence limits (Table 1).
Similarly, based on the odds ratio for control of bleeding,
hemostatic matrix was statistically superior to MPH at 5
(0.006, <0.001e0.037) and 10 min (0.009, 0.001e0.051) after
application (Fig. 2). The pig effect was significant at 5 and
10min andwasmaintained in this analysis; all other covariate
effects were not significant and were removed to compute the
odds ratios and their confidence limits (Table 1). The odds
ratios could not be performed at 2 min in both analyses
because hemostaticmatrix had a 100% success, which leads to
dividing by zero when the odds ratio is calculated. In com-
parison, MPH provided 82.5% success at 2 min.
Based on the mean difference of blood loss, MPH had a
greater rate of blood loss than hemostatic matrix 2 min after
application (mean difference: 0.1655 mL/min, 95% CI: 0.0088
to 0.3398) and significantly greater at 5 (0.3118, 0.0939e0.5296)
and 10min (0.5025, 0.2489e0.7561) (Table 2). The pig effect was
significant at 10 min in this model; all other covariate effects
were not significant and were removed to compute the mean
differences and their confidence limits.4. Discussion and conclusions
This study used a heparinized porcine hepatic abrasionmodel
to compare the hemostatic success, degree of bleeding, and
blood loss of lesions treated with MPH and hemostatic matrix.
Hemostatic matrix provided greater hemostatic success,
control of bleeding, and less blood loss thanMPH. Based on the
statistical analysis performed, hemostatic matrix was at least
29 times more likely to provide hemostatic success than MPH
at 5 min after application and 31 times more likely at 10 min
after application. Overall, the performance of hemostatic
matrix was superior to that of MPH in this animal model; as
such, the null hypothesis of equal hemostatic efficacy is
rejected.
This difference is likely due to the different mechanism of
action of each hemostatic agent. The mechanism of action oftatic success and superior control of bleeding than ARISTA
Baseline effect
P value
Odds ratio
(MPH/hemostatic
matrix)
95% confidence limit
Lower Upper
0.2195 0.035 0.004 0.278
0.2198 0.032 0.007 0.150
0.4391 0.006 <0.001 0.037
0.3345 0.009 0.001 0.051
ss and a proportional odds model on observed degree of bleeding.
dds ratios and their confidence limits. The odds of success is defined
atio, then, is the ratio of the odds of success for any two treatments. If
If the odds ratio is less than one, then hemostatic matrix is favored.
Fig. 2 e Floseal (hemostatic matrix) provides greater
control of bleeding than ARISTA AH (absorbable
hemostatic particles) in a heparinized porcine hepatic
abrasion model of a capsular tear. Statistical significance is
based on a proportional odds ratio (* 0.006, 95% CI:
<0.001e0.037; ** 0.009, 0.001e0.051; n [ 40 per group per
time point). (Error bars represent one plus or minus the
standard error based on normal approximation.)
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[2], whereas hemostaticmatrix activates platelets and actively
converts fibrinogen to fibrin by delivering thrombin to the
bleeding site [12e14]. In doing so, hemostatic matrix gelatin
conforms towound surfaces by absorbing tissue fluid to create
a tamponade effect [18]. The combination of these three
mechanisms of action is likely the reason for its greater effi-
cacy in this study and as reported by other investigators who
have used hypocoagulopathic, hypothermic, or hemodilute
animal models [11,18,19].
MPH induces coagulation through platelet plug formation
by concentrating blood solids. Platelet plug formation is
vulnerable to patient-specific conditions, that is, hypother-
mia and coagulopathy. Platelet adhesion is unequivocally
demonstrated to be defective in hypothermic patients
(33Ce37C) [20,21]. Platelet function is also negatively
impacted in heparinized patients due to the inactivation of
thrombin. Concurrent with our findings, MPH is not docu-
mented to be effective in heparinized patients or animal
models.
In a study by Bjo¨rses and Holst [8], MPH had a 20% (3 of 15)
success rate to treat a rodent partial nephrectomy model
heparinized to correct for interspecies variation. Ersoy et al. [5]Table 2 e Floseal (hemostatic matrix) provides superior reduct
particles).
Statistical analysis Time point after
treatment (min)
Pig effect
P value
Lobe effec
P value
Blood loss 2 0.4390 0.2020
5 0.1336 0.1071
10 0.0097 0.2544
Significance is based on a general linear model of mean difference in b
removed to compute the odds ratios and their confidence limits.and Neuffer et al. [22] have also reported that MPH is not
effective in severe bleeds. This may be because MPH absorbs
proteins up to 40,000 Da as it absorbs tissue fluid. In doing
so, a-thrombin (39,000 Da), b-thrombin (28,000 Da), and g-
thrombin (28,000 Da) [23,24] are sequestered into the hemo-
spheres from the bleeding site. Although this sequestration
does not inhibit coagulation, it may impede it leading to
multiple reapplications.
Ereth et al. [3] investigated the efficacy of MPH relative to
collagen sponge in a 6-mm diameter, 5-mm deep hepatic
punch biopsymodel in swine. In 33% of applications, MPH had
to be applied more than once. The authors did not state the
volume of MPH applied in each application. Murat et al. [2]
investigated the efficacy of MPH relative to oxidized cellu-
lose with bolster suture in a 2.5-cm-deep lower pole partial
nephrectomy model in swine. In 25% of applications, 10 g of
MPHhad to be appliedmore than once. In a follow-up study by
Murat et al. [4], a similar model was performed laparoscopi-
cally, in which 33.3% of applications required an additional 1 g
application more than once. Humphreys et al. [6] investigated
the efficacy of MPH in a 5- and 12-mm trocar lesion of the
spleen in swine; no comparator was used. In 42.8% of the 12-
mm lesions and 33.3% of the 5-mm lesions, 0.5 g of MPH had
to be applied more than once. Beyond the need for multiple
applications, several investigators report a short-lived clot.
MPH is epichlorohydrin cross-linked purified potato starch,
which is completely degraded by alpha amylase as quickly as
6 h after application [25]. The short lived clot created by MPH
may lead to continued postoperative bleeding requiring sur-
gical revision. In comparison, in a prospective, randomized
clinical study comparing hemostatic matrix with oxidized
cellulose and collagen sponge, use of hemostatic matrix led to
a 4.5% (5 of 110 patients) incidence of surgical revision
compared with a 13.5% (14 of 104 patients) incidence for low-
end hemostats similar to MPH [26]. The difference between
treatments was statistically significant (P ¼ 0.04). Concurrent
to the level of efficacy demonstrated by other investigators
and in this study, such a rapidly absorbed hemostatic agent is
most suited for low-level bleeding [5,22].
The fast degradation has minimal effect on treated tissue
[27]. Antisdel et al. demonstrated that MPH did not affect the
timing or extent of natural sinus mucosa healing relative to a
no treatment control after avulsion of the maxillary sinus
mucosa in rabbits. As with many absorbable hemostatic
agents, MPH is not to be placed in and around foramina of
bone, areas of bony confine, the spinal cord, and optic nerve orions in blood loss than ARISTA AH (absorbable hemostatic
t Baseline
effect
P value
Mean difference
(mL/min) (MPH-
hemostatic
matrix)
95% confidence limit
Lower Upper
0.5097 0.1655 (0.1733e0.0078) 0.0088 0.3398
0.4328 0.3118 (0.3255e0.0138) 0.0939 0.5296
0.9582 0.5025 (0.5272e0.0247) 0.2489 0.7561
lood loss (mL/min). Covariate effects that were not significant were
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with fluid. For comparison, hemostatic matrix has a
maximum swell of 10%e20% within 10 min.
This is the first study comparing the rate of blood loss after
treatment of MPH and hemostatic matrix. A limitation of this
metric is that the difference in blood loss is seemingly mini-
mal. At 2 min after application, MPH had a 0.16 mL/min
greater blood loss than hemostatic matrix, which increased to
0.5 mL/min 10 min after application. Due to the limited
intraoperative observation, it is not known whether the
increasing blood loss of MPH would plateau or continue to
increase, or whether hemostatic matrix would do so beyond
10 min. A longer intraoperative observation period is needed
to determine if or when the difference in rate of blood loss
stabilizes, converges, or continues to diverge.
This is the second study comparing the hemostatic efficacy
of MPH and hemostatic matrix, but the first clinically repre-
sentative comparison. The uniqueness of a porcine hepatic
abrasion model is that the model mimics a clinical lesion and
application of the hemostatic agents. Furthermore, the animal
model is heparinized to mimic the clinical condition of pa-
tients with underlying disease, such as those with renal [28] or
hepatic disease [29]. The strength of our study includes the
use of randomization, standardized side-by-side lesions, sta-
tistical power, and clinical relevancy. The limitation of our
study is that the hemostatic agents were only compared in
one tissue type. To address this, Bjo¨rses and Holst [8]
compared MPH and hemostatic matrix in a rodent partial
nephrectomy model, in which MPH provided a hemostatic
success rate of 20% and hemostatic matrix provided 100%
success rate. Although a small sample size was used by Bjo¨r-
ses, the efficacy differences agree between the animalmodels.
Overall, hemostatic matrix provided superior hemostatic
success, control of bleeding, and statistically significant less
blood loss thanMPH in a heparinized porcine hepatic abrasion
model of a parenchymal organ capsular tear. These findings
corroborate other MPH investigations regarding its efficacy
and suggest that MPH is not an appropriate surrogate for
flowable hemostatic matrix despite similar application tech-
niques. A direct clinical comparison, however, is needed to
determine the clinical impact of the greater efficacy of he-
mostatic matrix relative to MPH found in this animal model.
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